U.S. Pharmacist

Beware of Counterfeit Alli

By Staff


US Pharm. 2010;35(2):8.

Rockville, MD — The FDA has issued a warning regarding counterfeit versions of the OTC weight loss product Alli. The fake 60-mg capsules (120-count refill kit) contain the drug sibutramine, and not the active ingredient orlistat. Sibutramine (Meridia) is a prescription-only appetite suppressant that, based on new FDA warnings, should not be used in certain patient populations, such as those with a history of cardiovascular disease, and may cause adverse interactions with other medications. GlaxoSmithKline, the manufacturer of Alli, has determined that the look-alikes were sold over the Internet and not in retail stores. Consumers and health care professionals should report any suspected counterfeits to the FDA’s Office of Criminal Investigation and any adverse events to the FDA’s MedWatch Program.


U.S. Pharmacist is a monthly journal dedicated to providing the nation's pharmacists with up-to-date, authoritative, peer-reviewed clinical articles relevant to contemporary pharmacy practice in a variety of settings, including community pharmacy, hospitals, managed care systems, ambulatory care clinics, home care organizations, long-term care facilities, industry and academia. The publication is also useful to pharmacy technicians, students, other health professionals and individuals interested in health management. Pharmacists licensed in the U.S. can earn Continuing Education credits through Postgraduate Healthcare Education, LLC, accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Copyright © 2000 - 2015 Jobson Medical Information LLC unless otherwise noted.
All rights reserved. Reproduction in whole or in part without permission is prohibited.